Alnylam Pharmaceuticals
Tracked across 4 events · 32 articles · First seen Apr 29, 2026 · Last active Aug 16, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
On July 30, 2026, Alnylam Pharmaceuticals reported its second quarter 2026 financial results, announcing a reduction in its full-year 2026 TTR product sales guidance by approximately $200 million. The company attributed the cut to learnings…
Impact: Alnylam is the subject of the investigation and the company that cut its revenue guidance, causing a 28% stock drop. The guidance reduction and subsequent investigation negatively impact its financial outlook and investor confidence.
Jul 30, 2026 · 13 articles
Business
Impact: David Butler's earlier career at Alnylam contributed to LNP technology. Mentioned as background, no direct impact.
Aug 03, 2026 · 6 articles
Tech
Impact: Alnylam Pharmaceuticals is mentioned as the former employer of panelist John Maraganore.
Apr 29, 2026 · 7 articles
Regulatory
Impact: Alnylam licensed AG-236 to Agios, an siRNA therapy for polycythemia vera, part of Agios' broader pipeline.
Jul 07, 2026 · 6 articles
100
Alnylam Pharmaceuticals lowered guidanceAlnylam guidance cut...
80
Kessler Topaz Meltzer & Check launched investigation Alnylam PharmaceuticalsAlnylam guidance cut...
70
The Law Offices of Frank R. Cruz launched investigation Alnylam PharmaceuticalsAlnylam guidance cut...
ERGEN INTELLIGENCE
Track Alnylam Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard